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versité de Paris, Paris,In 2012, all Member States of the World Health Or-
ganization (WHO) endorsed a historical target to reduce
premature mortality from noncommunicable diseases
(NCD). This commitment was echoed in 2015 by the
United Nations Sustainable Development Goals, which
included a target to reduce premature mortality (the
measure of unfulfilled life expectancy and deaths between
the ages of 30 and 70 years) from NCD by 30% by the year
2030. The Sustainable Development Goals are especially
relevant to cardiovascular disease (CVD), the leading cause
of death globally, with increasing prevalence in low- and
middle-income countries (LMIC).
In support of reaching the Sustainable Development
Goals targets, the World Heart Federation (WHF) has
undertaken an initiative to develop a series of Roadmaps
[1e6] to 1) promote development of national policies and
health systems approaches; 2) identify potential roadblocks
to effective prevention, detection, and management of
CVD; and 3) provide strategies for overcoming roadblocks.
These Roadmaps (Figure 1) provide guidance for countries
to develop or update national NCD programs, using the
framework provided by the WHO Global Action Plan for
the Prevention and Control of NCD 2013 to 2020 [7]. The
aim of the WHF Roadmap initiative is to drive efforts
within national agendas to meet the ambitious targets set
out by the UN National Assembly in line with the WHF
strategy to translate science into policy and to influence
agencies, governments, and policy makers alike.
As care for patients living with heart failure involves the
patients, their families, nurses, dieticians, public health ex-
perts, general physicians, cardiologists, and dedicated heart
failure specialists, the WHF Heart Failure Roadmap is rele-
vant for all professionals caring for patients with this con-
dition. This document aims to provide comprehensive
guidance on the complex syndrome of heart failure from a
global perspective, by exploring the epidemiology of heart
failure, outlining evidence-based therapies that have been
shown to improve outcomes [8e10], creating a graphical
display of the ideal pathway for heart failure care, identifyingGLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214roadblocks, and providing potential solutions for over-
coming obstacles to prevention, diagnosis, treatment, and
monitoring, in addition to providing recommendations on
how to adapt and implement the Roadmap at a national level.
With the overall objective of reducing the burden of
heart failure globally, this Heart Failure Roadmap provides
WHF Members (including cardiac societies, foundations,
and associations) and policy makers with a framework to
guide initiatives within their national context, catalyze
initial discussions and plan a “call to action,” form
Roundtable discussions with key opinion leaders, and
leverage support and raise awareness for heart failure.METHODOLOGY AND SELECTION AND THE EXPERT
WRITING GROUP
To ensure a best practice approach and a consensus
document (Figure 2), the WHF Heart Failure Roadmap
was developed through review of published guidelines and
research papers, in consultation with a dedicated writing
group composed of experts in heart failure management
and health systems research. WHF regional Members were
invited to nominate an expert to the writing group to
ensure that the content of the Roadmap has true global
representation.
An extensive review of the applicability and acceptability
of the outlined roadblocks and proposed solutions was
conducted. A survey was sent to all WHF Members using
snowball sampling to widen the consultation, not only to
regional members, but also to national representatives. A
total of 146 responses was collated through this process,
offering feedback on the proposed Ideal Heart Failure
Continuum of Care Pathway (Figure 3) and the presented
roadblocks and solutions (Table 1). The results were
analyzed, open comments were reviewed and consolidated,
and the findings were incorporated into this document.
The development of the Heart Failure Roadmap forms
part of a larger global project that seeks to create living
documents that inform initiatives in response to the global197
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198needs of patients with CVD. Using publication as a first
step in organizing and establishing consensus on the heart
failure “care gap,” the WHF Heart Failure Roadmap can be
used as a springboard to initiate a call for action and pre-
scribe measurable steps toward a common goal, at national
and international levels.HEART FAILURE DEFINITION“Heart failure is a complex clinical syndrome caused
by any cardiac structural and/or functional abnor-
mality that results in impairment of ventricular filling
or ejection of blood” [9].Heart failure can present acutely or as a progressive
disease characterized by worsening shortness of breath,
coughing or wheezing, tiredness and fatigue, fluid reten-
tion with swelling of the legs and/or abdomen, and/or
reduced ability to do physically demanding tasks or exer-
cise [8].
Central to diagnosing heart failure is the demonstra-
tion of underlying structural and/or functional cardiac
abnormalities. Accepted definitions used to categorize
heart failure include [8,9]: heart failure with reduced
ejection fraction ([HFrEF]; left ventricular ejection fraction
[LVEF] <40%); heart failure with preserved ejection frac-
tion (LVEF 50%); and heart failure with midrange ejec-
tion fraction (LVEF 40% to 49%). Patients with heart
failure with preserved ejection fraction often have history
of hypertension and/or atrial fibrillation [10], whereas pa-
tients with HFrEF are often younger and may have a his-
tory of ischemic heart disease or cardiomyopathy (Online
Tables 1 and 2) [11e15].RELEVANCE OF HEART FAILURE TO THE GLOBAL
BURDEN OF CVD
It has been estimated that there are approximately 26
million cases of heart failure worldwide [15]. This does not
account for the cases of heart failure that are undiagnosed
or misdiagnosed and, therefore, a true estimate of the
global burden heart failure remains unclear [16]. Mortality
rates for heart failure patients remain high with 17% to
45% of deaths occurring within 1 year of diagnosis—with
the majority of deaths occurring within 5 years of admis-
sion [8].
Of the annual 17.9 million cardiovascular-related
deaths worldwide, 80% occur within LMIC [15,17e19],
a trend replicated in heart failure where mortality rates are
higher in these regions [18e21]. Despite this, our under-
standing of heart failure is largely based on studies un-
dertaken in high-income countries and building a picture
that truly reflects the epidemiology of heart failure across
all regions, especially LMIC where mortality risk and spe-
cific death causes from heart failure are still largely unex-
plained [17], remains a challenge.The few data available clearly show that the prognosis
in heart failure varies according to geographic area [8].
One-year death rates in patients with heart failure remain
high in LMIC, reaching 34% in Africa, 23% in India, 15%
in South East Asia, 9% in South America, and 7% in China
[17]. Disparities in patient outcomes may be explained by
differences in the severity of heart failure at presentation,
available therapies, resources, and health care systems [20].
However, further analysis of specific causes of death and
related comorbidities is needed to improve patient care.
Numerous causes of heart failure have been described
including infectious diseases (Chagas and rheumatic heart
disease) and cardiac conditions (hypertension, heart mus-
cle disease, coronary heart disease, valve disease, congenital
heart disease, pericardial disease, cor pulmonale, and
rhythm disorders) [8]. Figure 4 highlights the most com-
mon causes contributing to heart failure by region
[17,22,23]. It is evident from this regional map that
ischemic heart disease and hypertension are the most
common causes of heart failure globally.
SUMMARY OF HEART FAILURE
MANAGEMENT GUIDELINES
To prevent the development of the heart failure syndrome,
one needs to address its most common causes (e.g., hy-
pertension, ischemic heart disease, rheumatic heart disease)
and, ideally, should consider screening for asymptomatic
left ventricular (LV) dysfunction in high-risk individuals
(Online Table 2) [8,11e15].
The goals of heart failure management are to 1) treat
the underlying cause; 2) improve clinical status, functional
capacity, and quality of life; 3) prevent hospitalizations;
and 4) reduce mortality. Drug therapy for the treatment of
the clinical syndrome of heart failure includes diuretic
agents to relieve the signs and symptoms of congestion and
disease-modifying therapies, such as angiotensin-
converting enzyme inhibitors (or angiotensin receptor
blockers), beta-blockers, mineralocorticoid receptor an-
tagonists, angiotensin-receptor-neprilysin inhibitor, and
ivabradine. These drugs have been shown to reduce hos-
pitalization and improve survival when used as specified by
the guidelines [8,9]. Additional therapies, such as
hydralazine-isosorbide dinitrate and digoxin, may be used
in symptomatic patients with HFrEF. Device therapy (e.g.,
cardiac resynchronization therapy, implantable
cardioverter-defibrillators, LV assist devices) and heart
transplantation may be indicated in selected patients with
advanced disease. Table 2 represents a summary of heart
failure guidelines from European Society of Cardiology and
American College of Cardiology/American Heart
Association.
CARE GAP AND THE IDEAL HEALTH CARE JOURNEY
FOR HEART FAILURE
The “care gap” refers to the difference between optimal,
evidence-based, guideline-recommended care and what isGLOBAL HEART, VOL. 14, NO. 3, 2019
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delivered in practice. Although the care gap may be
considered larger in LMIC, disparities have been reported
in screening, diagnosis, treatment, and monitoring of pa-
tients across all income settings. The ideal pathway of care
(referred to in this Roadmap as the “continuum of care
pathway”) was developed using an evidence-informed
approach and considers the entire journey of the patient
and a best-practice treatment approach.
The Ideal Journey for Heart Failure Patients
Each step along the heart failure journey is important, with
many shared determining factors, regardless of local and
regional differences in resources or health service delivery.
The continuum of care focuses on a common pathway for
heart failure patients (Figure 3) and includes identifying
individuals at risk, diagnosing heart failure, outlining
necessary investigations, treatment initiation, and follow-
up. The aim of this section is not to reiterate published
guidelines, but rather to investigate best-practice ap-
proaches for each step in the care pathway and to identify
important stakeholders that may strengthen health care
delivery to patients with heart failure.
Heart Failure Prevention. General Population: There is
considerable evidence that the onset of heart failure may be
delayed or prevented through interventions aimed at
modifying risk factors, as outlined in previously published
WHF Roadmaps (Figure 1) [1e6]. Heart failure prevention
strategies (Figure 3) are not dissimilar to those across the
spectrum of CVD, and it is, therefore, appropriate to
dedicate time and effort on key primary prevention stra-
tegies such as smoking cessation [21,24], alcohol reduction
or cessation [25], exercise training [26], as well as sec-
ondary prevention measures, as described in previous
Roadmaps.
Opportunistic Screening and Diagnosis. Individual at
Risk: Screening plays an essential role in the early diagnosis
of heart disease and is useful in identifying those at higher
risk of developing heart failure. Screening needs to be
adapted according to affordability and availability of a
health care system and the different underlying causes per
region. Globally underlying causes of heart failure include
hypertension (the most common cause of heart failure),
myocardial infarction, diabetes, and valvular heart disease,
including rheumatic heart disease and cardiomyopathies
[27e29]. In addition to those with traditional CVD risk
factors, individuals at increased risk of developing heart
failure include peripartum women, those who have
received chemotherapy, individuals with systemic inflam-
matory conditions, and those with a positive family history
of heart disease or sudden cardiac death (Figure 3).
Regional and national guidelines in acute and chronic
heart failure offer quality recommendations in the diag-
nosis and management of heart failure, yet for a number of
reasons including poor adherence and health economic
factors, these recommendations lead to a gap betweenGLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214best-practice recommendations and implementation [8].
Careful history taking, systematic clinical examination, and
appropriate investigations are necessary to follow a best-
practice approach [9]. A woman’s pregnancy history is an
integral part of her assessment and pregnancy-related di-
agnoses, such as pre-eclampsia, eclampsia, or gestational
diabetes, could signal premature development of CVD with
a 4-fold risk of incident heart failure [30].
Despite resource limitations, a diagnosis of heart failure
can be made at the primary care level. Careful assessment
of symptoms (breathlessness, ankle swelling, and fatigue)
and signs (elevated jugular venous pressure, pulmonary
crackles, and peripheral edema) can be helpful, but may
not be sufficient to confirm a diagnosis of heart failure [8].
The electrocardiogram (ECG) is widely recognized as
having an essential role in the diagnosis of underlying
cardiac disease [8,9], and, whereas an abnormal ECG has
low specificity [31], heart failure is highly unlikely to be
present if the ECG is completely normal [32]. Basic in-
vestigations, including biomarkers (B-type natriuretic
peptide, N-terminal proeB-type natriuretic peptide), ECG,
and focused point-of-care echocardiogram, are useful tools
for screening high-risk individuals and confirming a diag-
nosis of heart failure and, ideally should be accessible at
primary care facilities. Future artificial intelligence-enabled
“smart” tools for both ECG [33] and echocardiography
[34] may further enhance early detection of heart failure at
the community level. Patients diagnosed with heart failure
usually require referral to higher levels of care for more
comprehensive clinical evaluation and investigation,
particularly those with advanced disease, to confirm and
manage the underlying cardiac condition. A table of diag-
nostic investigations can be found in Online Table 2
[8,11e15].
Treatment: Initiation of Guideline-Based Therapy
and/or Treatment of the Specific Cause. New-onset
heart failure requires urgent initiation of therapy [35].
Heart failure management requires the use of: 1) a
guideline-based approach with pharmacological and/or
nonpharmacological therapies [9]; 2) a patient-centered
approach promoting shared decision making with pa-
tients [36]; and 3) patient education to improve treatment
adherence [37]. Regardless of whether a patient presents
with asymptomatic LV dysfunction or overt heart failure,
careful consideration of their history and examination is
required to implement an appropriate guideline-based
treatment plan [8] (Figure 3, Table 2, Online Table 3).
Heart failure is a clinical syndrome, and a compre-
hensive diagnosis is dependent on the demonstration of an
underlying cardiac cause to ensure appropriate and specific
treatment [8]. The diagnostic work-up of the underlying
cardiac cause should therefore be conducted in conjunc-
tion with the therapeutic management of the heart failure
syndrome. Furthermore, to provide holistic care to heart
failure patients, other medical and social cofactors, such as
concomitant comorbidities, contraception, vaccination,199
Secondary
Tobacco
Control
Hypertension
Heart
Disease
Driving
to reduce the
burden of NCDs
Atrial
Cholesterol
Heart Failure
CVD and
Diabetes
Chagas
FIGURE 1. The WHF roadmap initiative. CVD, cardiovascular disease; NCD,
noncommunicable diseases; WHF, World Heart Federation.
Assemble Expert Group
Statement of Intent
including purpose,
target audience, scope
Survey through WHF
members
Snowball sampling
Capturing an audience
and summary documents
Monitoring and
FIGURE 2. The design and methodology framework. WHF, World Heart
Federation.
j gRECS
200nutrition, work, driving, and transportation, need to be
addressed simultaneously.
Monitoring and Follow-Up: Stable Patient Follow-
Up as per Guidelines. Monitoring and follow-up are
an essential part in the overall management of heart failure
and are discussed in detail in the published guidelines (see
Figure 3). The primary goal in monitoring and follow-up is
to detect possible decompensation (worsening heart fail-
ure) and prescribe appropriate therapy as early as possible.
This may be achieved through consultation in a heath care
facility, via telephone or, more recently, through the use of
mobile health (mHealth) packages [38].
PERSPECTIVES ON HEART FAILURE
Heart failure is a chronic, progressive condition with a poor
prognosis if left untreated [39]. For the purpose of this
Roadmap, barriers and possible solutions to care will be
presented from the perspective of: 1) patients, families,
communities, patient organizations, and civil society;
2) health care professionals, including clinicians and allied
health professionals; and 3) decision makers, nonprofit
organizations, government officials, and leaders in heart
failure.
Heart failure can be a life-changing and debilitating
disease [40]. The diagnosis may lead to inaccurate as-
sumptions and misconceptions about the condition
[41e43]. The gradual decline of patients with heart failure,
often interrupted by episodes of acute deterioration,
recurrent hospitalizations, or sudden unexpected death can
have devastating effects on both patients and their families
[44]."A lot of people with heart failure think that’s the end
of their lives, as soon as they get a diagnosis. I did at
first, I thought, that’s it." "With heart failure it’s very
unknown, people just don’t know what it is" [45].Differences in perspectives between patients and health
care professionals may affect patient care. One study re-
ported that patients and caregivers believed that “trouble
breathing” was a reason for hospitalization, whereas clini-
cians identified nonadherence to diet and medications,
progression of disease, and various socioeconomic factors,
such as a lack of social support and access to medications,
as reasons for hospital admissions. The investigators sug-
gest that health care workers may not recognize some of
the biggest challenges facing heart failure patients [46]. The
Handbook of Multidisciplinary and Integrated Heart Failure
Care supports a patient-centeredecare approach that is
flexible and adaptable to the patients’ needs [47]
(Figure 5). The purpose of this Roadmap is to propose
strategies and interventions to improve the care of patients
with heart failure across all settings. A unified approach to
care requires an improved understanding and appreciation
of the daily challenges faced by patients and caregivers,
dedicated funding, and well-designed health systems that
meet the specific needs of these patients.GLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214
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TABLE 1. Roadblocks and solutions
Level Roadblocks Potential Solutions
Prevention of Heart Failure
Patient factors Lack of patient education and awareness
Lack of affordability of healthier lifestyle choices and
therapies to address risk factors
Develop public awareness programs about risk factors
and HF
Implement community-based healthy living programs
Health care workers Lack of education and/or training among physicians
about the importance of HF screening and
prevention
Physician apathy and/or lack of incentive
Improve HF awareness among health care
professionals
Address risk factors for CVD using WHF Roadmaps and
published guidelines—emphasis on identifying
individuals at risk and preventative strategies
Health care systems Lack of patient education programs
Environmental barriers to lifestyle modification
Lack of training initiatives for health care workers
Lack of country-specific protocols for screening
Lack of, or inadequately supported, screening
programs—staff, equipment, space
Engage at government level between sectors to
address education and environmental barriers
Subsidize training initiatives
Develop region-specific protocols for screening
Provide government-subsidized screening programs
Diagnosis of Heart Failure—Factors That Delay Diagnosis and Result in Delayed Treatment Initiation
Patient factors Limited access to health care facilities with sufficient
expertise to diagnose HF
Affordability of specialized investigations
Late presentation due to socioeconomic status, poor
education, or rural isolation
Patient fears, social implications, and stigma of having a
diagnosis of HF
Standardize costs for investigation, lobby for
government-driven cost subsidies for essential
diagnostic investigations
Engage across multiple sectors to improve
socioeconomic status, education, living conditions,
road access, transportation services
Engage in the community to improve patient awareness
and education
Health care workers Lack of education and training among physicians about
HF diagnosis and treatment
Lack of downstream support from specialist services to
facilitate referral
Improve awareness of diagnostic criteria and clinical
practice guidelines
Facilitate interaction between primary level health care
workers and specialists
Health care systems Resource limitations at the various levels of care
Lack of the appropriate tests/equipment to make a HF
diagnosis—ECG, echocardiogram, natriuretic
peptide
Lack of funding for experienced and/or qualified staff
Provide access to investigations necessary to diagnose
or exclude HF at a primary care level—e.g.,
natriuretic peptide, point-of-care echocardiography
Implement health care worker outreach programs
Establish referral protocols to ensure equity of care—
accessibility to diagnostic services
Treatment of Heart Failure—Accessibility and Affordability of Therapies
Patient factors Out-of-pocket expenditure for medications,
hospitalization, or intervention
Adherence on treatment
Failure to attend follow-up—travel time and transport
cost, leave from work, lack of child-care services,
impaired mobility due to advanced disease
Patient fears and lack of understanding about HF
treatment
Advanced disease at presentation due to late
presentation to health care facility
Ensure availability of application for disability
compensation, if appropriate, and engage with
employers
Address adherence to treatment
Disseminate patient education (pamphlets, waiting
room education initiatives, nurse-driven
counseling) to improve patient awareness
Promote patient-driven HF associations and family
and/or community engagement
(continued)
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TABLE 1. Continued
Level Roadblocks Potential Solutions
Health care workers Clinician inexperience and lack of adherence to
guidelines
Poor tolerability of drugs due to inadequately treated
congestion, side effects, or rapid titration
Management challenges related to persistent
congestion
Inadequate dosing of diuretic therapy, poor
absorption of oral diuretics, diuretic resistance
Reduced renal perfusion and/or renal impairment
Failure to optimize drug therapies directed at
neurohormonal activation (RAAS)
Failure to titrate doses of medical drug therapies
Infrequent follow-up
Failure to identify and manage precipitating factors
(e.g., anemia) and comorbidities
Failure to identify and treat underlying cause of HF
Failure to refer patients for advanced HF therapies
(e.g., drug therapies, devices, transplant, surgery,
percutaneous intervention)
Lack of knowledge about available services for
advanced HF care
Offer periodic training of health care professionals
Provide summarized guideline-based protocols to
assist clinicians in practice
Disseminate clinician education on drug therapy side
effects, titration protocols, red flags, monitoring
(e.g., digoxin toxicity)
Develop problem-based training initiatives for doctors
and nurses
Dosing of diuretic agents and use of combination
diuretic therapy
Indications for hospitalization for IV diuresis
(–inotropes)
Monitoring of renal function and management of
renal impairment in HF
Introduction and titration of disease-modifying
therapies
Counsel patients regarding adherence, potential drug
side effects, fluid and salt restriction, weight-
guided adjusted diuretic therapy
Establish nurse-run clinics for follow-up
Standardize investigations in HF at different levels of
care, aimed at identifying etiologies, precipitating
factors, and comorbidities
Develop referral protocols specific to local resources
and services to facilitate appropriate referral
Health care systems Lack of availability of essential medications
Lack of affordability of essential medications
Lack of monitoring of drug quality
Lack of standardized procurement protocols
Pharmacy administrative challenges and stock-outs
Lack of appropriately trained pharmacists
Lack of advanced HF specialist services
Lack of surgical and percutaneous intervention
expertise and/or facilities
Lack of rehabilitation services
Lack of palliative care programs
Prolonged waiting periods related to service delivery
Create a national EDL listing of essential medications
Ensure availability of EDL-listed drug therapy
Implement quality assurance strategies
Implement cost-reducing strategies—development
and procurement of generic therapies,
standardization of drug costs, tendered
procurement of drugs
Lobby for government-subsidized care
Develop HF-specific services at various levels of care
Develop industry-related initiatives to reduce costs of
devices and equipment
Encourage private fundraising initiatives
Collaborate with NGO and government
Invest in HF-directed research initiatives—directed at
new and affordable therapies, evidence-based
health care performance measures, cause and
effect
Develop e-health platforms for monitoring
CVD, cardiovascular disease; ECG, electrocardiogram; EDL, essential drug list; HF, heart failure; IV, intravenous; NGO; nongovernmental organization; RAAS, renin-angiotensin-
aldosterone system; WHF, World Heart Federation.
gRECSjROADBLOCKS AND SOLUTIONS
This section of the WHF Heart Failure Roadmap has been
developed in consultation with WHF Members who were
offered the opportunity to comment, via a WHF survey, on
proposed roadblocks and solutions relevant to their spe-
cific contexts. WHF Members were asked to comment on
the following: 1) the setting for care; 2) the roadblock(s)GLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214and evidence; 3) an integrated approach to specific solu-
tions; and 4) examples of initiatives that have been
implemented in practice. A summary of the identified
roadblocks and possible solutions is presented in Table 1.
The WHF survey, rolled out using the snowball sampling
method, gathered >100 responses regarding key questions
linked to the proposed ideal pathway of care for heart203
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Cardiomyopathy, 16.6% 
Hypertension, 14%
Valve disease, 11%
Middle East
INTER-CHF,
n=1,000
Ischaemic HD, 50%
Cardiomyopathy, 18.6% 
Hypertension, 10%
Valve disease, 8%
Europe
ESC-HF, CHF
n=7,173
Ischaemic HD, 43.1%
Co-exis ng
hypertension, 58.3%
Co-exis ng AF, 37.7%
North America and
Europe combined
HHF Registries,
n > 250,000
Ischaemic HD, >50%
Co-exis ng
hypertension, 70%
Co-exis ng AF, 40%
NORTH AMERICA
AND EUROPE
COMBINED
HHF REGISTRIES
Africa
INTER-CHF, n=1,294
Hypertension, 35%
Ischaemic, 20%
Cardiomyopathy, 14.2%
Valve disease, 11%
THESUS-HF, n=1,006
Hypertension, 45.4%
Cardiomyopathy, 30.4%
Rheuma c HD, 14.3%
Ischaemic HD, 7.7%
FIGURE 4. Most common causes of HF geographically. HHF (Hospitalized Heart Failure) Registries include ADHERE (Acute Decompensated
Heart Failure National Registry); ADHERE-AP (Acute Decompensated Heart Failure National Registry International—Asia Pacific); AHEAD (Acute
Heart Failure Database); ALARM-HF (Acute Heart Failure Global Registry of Standard Treatment); ATTEND (Acute Decompensated Heart Failure
Syndromes); EFICA (Epidémiologie Francaise de l’Insuffisance Cardiaque Aigue); EHFS II (European Heart Failure Survey II); ESC-HF (European
Society of Cardiology—Heart Failure); GWTG-HF (Get With The GuidelineseHeart Failure); IN-HF (Italian Registry on Heart Failure); OPTIMIZE-HF
(Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure), RO-AHFS (Romanian Acute Heart Failure
Syndromes); THESUS-HF (The Sub-Saharan Africa Survey of Heart Failure) [22], INTER-CHF (International Congestive Heart Failure) [17], Hunter
HF [23]. AF, atrial fibrillation; HD, heart disease.
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204failure. Information gathered from this survey has enabled
us to focus on high priority areas and to include specific
examples of interventions and evidence in practice.
Note: Within this section not all roadblocks and so-
lutions are discussed. The focus has been targeted on the
areas that received highest levels of agreement within the
WHF survey results from April 2019, with support from
reported roadblocks from published findings.
Screening and Early Diagnosis
Setting: General Public and Civil Society.
A “low level of understanding among patients with
heart failure” was the highest ranked perceived roadblock
in early diagnosis; almost 48% of survey respondents cited
this as the highest, or second highest, priority area in the
prevention of heart failure in the general population. In
addition, a well-noted barrier in both the published reports
and the WHF survey, was “a low level of awareness and
knowledge on symptoms of heart failure among health care
professionals, particularly at primary care level” [42], and
“the general public” (SHAPE [Study Group on HF
Awareness and Perception in Europe] study) [48,49]. More
recent studies reiterate that awareness of heart failure has
not improved in the past 10 years, despite a rising inci-
dence of heart failure worldwide, with a reported lifetime
risk of 1 in 5 [50]. Low awareness of the symptoms
associated with heart failure in communities may delay the
presentation of patients to a health care facility, potentiallypostponing diagnosis and treatment. Heart failure has and
continues to be fraught with misunderstandings, inaccur-
acies, and misconceptions [43].
Possible solutions to overcome low awareness of heart
failure requires local, national, regional, and international
efforts to improve the public’s understanding of heart failure
using all possible communication channels and community-
based healthy living programs. The website www.
heartfailurematters.org is a useful and easy-to-access
source of information for patients, families, and caregivers,
and is translated into 9 languages [51]. European Heart
Failure Awareness Week, Heart Failure Awareness Week—
“Do Your Part, Know Your Heart” Campaign (Heart Failure
Society of America) and “Keep it Pumping” Campaign
(Cardiology Society of India) are examples of programs
designed to create awareness among patients and caregivers
and gather the support of national societies. Whereas evi-
dence is lacking in the effectiveness of awareness campaigns
in heart failure specifically, research in other disease areas
indicates that increased awareness directly correlates with
earlier detection anddiagnosis [52,53]. The key action area is
to create open, direct, and innovative communication op-
portunities that all people involved in the global fight against
heart failure can actively support.
Screening
Screening patients for asymptomatic LV systolic dysfunc-
tion, risk of heart failure, or minimal symptoms such asGLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214
TABLE 2. Summary of HF treatment guidelines
ESC 2016 (Evidence Class, Level) ACCF/AHA 2013/2016 (Evidence Class, Level)
Recommended therapies to
prevent or delay the onset
of HF
ACCF/AHA Stages A and B
Treatment of hypertension (I, A)
Treatment with statins in patients with CAD or at high
risk of CAD (I, A)
ACE-I can be considered in patients with
asymptomatic LV dysfunction with or without a
prior MI (I, A; I, B). ACE-I can be considered in
patients with stable CAD regardless of LVEF (IIa, A)
BB in asymptomatic LV dysfunction and prior MI (I, B)
Empagliflozin can be considered in DM2 (IIa, B)
Lifestyle modification—smoking cessation (I, C),
alcohol intake reduction (I, C), other risk factors
reduction (IIa, C)
Stage A:
Treatment of hypertension and lipid disorders (I, A)
Treatment of other conditions—obesity, DM, tobacco
use, and cardiotoxic agent avoidance (I, C)
Stage B:
ACE-I in asymptomatic patients with reduced EF with
or without a history of MI or ACS (I, A) and BB in
asymptomatic patients with reduced EF with (I, B)
or without (I, C) a history of MI and/or ACS
Statins in patientswith a history ofMI and/or ACS (I, A)
Treatment of hypertension (I, A)
Diuretics to relieve symptoms
and signs of congestive HF
ACCF/AHA Stages C and D
Diuretics are recommended to reduce signs and
symptoms of congestion (I, B). Loop diuretic agents
produce a more intense and shorter diuresis than
thiazides. The combination may be used to treat
resistant edema
Diuretics are recommended in patients with HFrEF
who have evidence of fluid retention to improve
symptoms (I, C). Loop diuretic agents are
preferred; however, thiazide diuretic agents may
be considered in hypertensive patients with mild
fluid retention
Recommended first-line OMT
for symptomatic HF—see
guidelines for details on
dose titration
ACE-I and BB are recommended in patients with HFrEF
(I, A)
ACE-I and BB (bisoprolol, carvedilol, or metoprolol)
are recommended in all patients with HFrEF (I, A)
ACCF/AHA Stages C and D MRA is recommended for patients with HFrEF who
remain symptomatic despite treatment with an
ACE-I and a BB (I, A)
MRA is recommended in patients with NYHA
functional class IIeIV HF with LVEF £35% (I, A), or
following an acute MI in patients with LVEF £40%
who develop HF or have DM (I, B)—see guidelines
for strategies to minimize hyperkalemia
ARB can be used in ACE-Ieintolerant patients (I, B) ARB can be used in ACE-Ieintolerant patients (I, A)
Recommended therapies
(where resources allow) in
patients with LVEF 35%
that remain symptomatic
despite first-line OMT
Drug therapies:
Ivabradine for patients in sinus rhythm with HR 70
beats/min (IIa, B), or in patients unable to tolerate
BB (IIb, C)
ARNI to replace ACE-I in symptomatic patients (able to
tolerate ACE-I or ARB and on OMT) (I, B)
Drug therapies:
Ivabradine may be used in patients in sinus rhythm
with HR 70 beats/min, on OMT including
maximal tolerate BB dose
ARNI may be used in conjunction with a BB and MRA
in selected patients with HFrEF (I, B-R)
ACCF/AHA Stages C and D Device therapies (only I, A/B recommendations):
CRT for symptomatic patients with HF in sinus rhythm
and LBBB, with QRS interval ‡150 ms (I, A), or QRS
interval 130 to 149 (I, B). Consider CRT rather than
RV pacing for patients with an indication for
ventricular pacing and high-degree AV block
ICD for patients with LVEF £35% despite OMT (IHD—I,
A; DCM—I, B) or history of a VT/VF (I, A)
Device therapies (only I, A recommendations listed):
CRT for patients with LVEF £35%, sinus rhythm, LBBB,
QRS interval ‡150 ms and Class II to IV
(ambulatory) symptoms (I, A for Class III/IV, and I,
B for Class II)
ICD for primary prevention of SCD in selected patients
with LVEF £35% and NYHA functional class II/III
symptoms on OMTwith an expected survival of >1
yr (I, A) (at least 40 days post-MI, if present)
Mechanical circulatory support and transplantation as
per guidelines
Mechanical circulatory support and transplantation as
per guidelines (Stage D)
Additional therapies for
symptomatic patients with
HFrEF
ACCF/AHA Stage C and D
Digoxin may be considered in patients in sinus rhythm
on OMT to reduce hospitalizations (IIb, B)
Combination of hydralazine and isosorbide dinitrate
can be considered in black patients on OMT (IIa, B),
or in patients unable to tolerate ACE-I/ARB (IIb, B)
Digoxin can be given to patients with HFrEF (IIa, B)
The combination of hydralazine and isosorbide
dinitrate is recommended for African Americans
with NYHA functional class III to IV HFrEF
receiving OMT with ACE-I and BB (I, A) or in
patients who cannot be given an ACE-I or ARB
(IIa, B)
(continued)
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TABLE 2. Continued
ESC 2016 (Evidence Class, Level) ACCF/AHA 2013/2016 (Evidence Class, Level)
Treatments with unproven
benefit in symptomatic
patients in HFrEF
Statins (unless otherwise indicated); anticoagulation or
antiplatelet therapy (unless otherwise indicated);
renin inhibitors
Nutritional supplements, hormonal therapies
Treatments that may cause
harm in patients with HFrEF
Thiazolidinediones, NSAID or COX-2 inhibitors,
diltiazem, verapamil, ARB in combination with
ACE-I and MRA, ARNI in combination with ACE-I,
CRT is contraindicated if QRS interval is £130 ms
Verapamil, ARB in combination with ACE-I and MRA,
long-term infused positive inotropic agents, ARNI
should not be given in patients with a history of
angioedema or with an ACE-I (36-h washout
period)
ACCF/AHA stages are defined as follows: Stage A as being at high risk but without structural heart disease or symptoms of HF; Stage B as structural heart disease but without
signs or symptoms of HF; Stage C as structural heart disease with prior or current symptoms of HF; and Stage D as refractory HF requiring specialized interventions.
ACCF, American College of Cardiology Foundation; ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AHA, American Heart Association; ARB,
angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AV, atrioventricular; BB, beta-blocker; CAD, coronary artery disease; COX-2, cyclooxygenase 2;
CRT, cardiac resynchronization therapy; DCM, dilated cardiomyopathy; DM2, diabetes mellitus type 2; ESC, European Society of Cardiology; HF, heart failure; HFrEF, heart
failure with reduced ejection fraction; HR, heart rate; ICD, implantable cardioverter-defibrillator; IHD, ischemic heart disease; LBBB, left bundle branch block; LV, left ven-
tricular; LVEF, left ventricular ejection fraction; OMT, optimal medical therapy; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NSAID, nonsteroidal
anti-inflammatory drugs; NYHA, New York Heart Association; RV, right ventricular; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.
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206mild dyspnea is not straightforward and there is no
single investigation that can conclusively confirm a
diagnosis of heart failure [9]. Evidence continues to
emerge for implementing standardized screening for
heart failure [54]. Screening of high-risk patients using
algorithms such as the SCORE (Systematic COronary
Risk Evaluation) Risk Charts or the Framingham risk
calculator have reported mixed success [55]. Targeting
high-risk populations require effective strategies for
identifying at-risk patients within clinical practice [55].
Whereas current guidelines underline the importance of
natriuretic peptides for the purpose of early diagnosis of
heart failure, evidence is building in support of their use
in prevention and screening in high-risk individuals
[54e56]. Examples of the use of natriuretic peptides in
practice is further discussed within the diagnostic section
of this document.
For an integrated approach to improving awareness of
heart failure, see Table 3 [54,57,58].civil society
AN
INTEGRATED
APPROACH TO
PATIENT CARE
Leaders in
cardiovascular
health,
decision and
policy
makers
Health care
professionals
FIGURE 5. An integrated approach to patient care.Diagnosis
Setting: Primary Care, Community Care, Specialist Centers.
Making an accurate comprehensive diagnosis requires
a range of diagnostic tools and information, in conjunction
with clinical judgment and expert knowledge. Whereas the
diagnosis of patients presenting with the classic symptoms
of heart failure can be relatively straightforward [59], it can
be more difficult in the early stages of disease when
symptoms and signs may be less obvious, particularly if
there is limited availability of the necessary investigative
modalities [32]. A number of studies have sought to
investigate clinically relevant diagnostic research at the
primary care level in the detection of heart failure [60e62]
subsequently confirmed following investigations by a
cardiologist at a specialist clinic [61].An Integrated Approach to Address Roadblocks to
Diagnosis, Examples in Practice. Limited investigations
at primary care level: The role of primary care in the
detection and diagnosis of heart failure is critical [63].
Disparities in the diagnosis and management of heartGLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214
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failure patients have been reported in various studies
worldwide, highlighting the importance of training health
care providers within the primary care settings to improve
patient outcomes. One example in practice was the launch
of the One Simple Blood Test campaign by the Pumping
Marvellous Foundation in the United Kingdom to raise
awareness among general practitioners on the use of
natriuretic peptides testing to facilitate earlier diagnosis of
heart failure at the primary care level [64e66]. There are
an increasing number of studies that support the use of
natriuretic peptides biomarkers in early detection of heart
failure [9,65,66].
Improving access to diagnostic tests: Late presentation of
heart failure patients (due to poor socioeconomic status,
low levels of education or rural isolation) was the highest
ranked roadblock related to diagnosis from the WHF
survey, with 89% of survey respondents in agreement.
Another frequently cited roadblock was access to specialist
clinics for diagnosis and management of heart disease.
Echocardiography is the single most important diagnostic
imaging technique [67], yet 10% to 25% of patients
admitted to hospitals in Europe and the United States with
a primary diagnosis of heart failure do not undergo echo-
cardiography [68]. Overcoming this barrier requires: 1) the
improvement of service delivery models; and 2) upskilling
and task shifting of specific skills of health care workers
along the care pathway.
For early detection and diagnosis, there is a need to
commission cost-effective testing opportunities, most
notably for echocardiography [8] and natriuretic peptides
[69] to facilitate the diagnosis of heart failure. Both these
recommendations are set forth in the 2016 Focus on Heart
Failure report [70]. It is well recognized that CVD is common
in LMIC, and 44% of patients with newly diagnosed CVD
present with heart failure [71]. In Africa, a large percentage of
the population simply do not have access to the necessary
care, with limited access to doctors, particularly specialists
residing in capital cities, and have challenges associated with
transportation, particularly in rural areas [72].
The following example tells a compelling story of an
effort, supported of the Rwandan Ministry of Health, to
reach a large at-risk population in Rwanda. With an aim of
decentralizing services for heart failure, integrated nurse-
led and physician-supervised clinics were set up in 2 ru-
ral public-sector district hospitals. A strategy to disseminate
the use of portable echocardiography and simplified algo-
rithms for diagnosis was established. Nurses were trained
to perform and interpret limited echocardiographic studies
using visual qualitative inspection to make a preliminary
diagnosis, with a confirmatory diagnosis made following
referral to a cardiologist. This simplified approach to early
diagnosis in a resource-limited setting is just an example of
how to provide care in difficult-to-reach populations [73].
Access to specialist care at a district level can also be ach-
ieved by arranging rotational specialist visits and may help
to address a number of reported roadblocks along this care
pathway.GLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214For an integrated approach to improve access to
diagnostic tests, see Table 4 [74,75].Treatment
Setting: Specialist centers, primary care, community care
centers, home care visits.
The aim of heart failure treatment is to improve life
expectancy and quality of life [76]. Within the pathway of
care, initiation of treatment and therapeutic strategies for
heart failure patients varies considerably depending on the
cause of heart failure. Patients with asymptomatic LV sys-
tolic dysfunction may follow a treatment pathway that
differs considerably from the approach for patients with
overt heart failure following a cardiac event [9]. Deter-
mining the primary diagnosis can be particularly chal-
lenging in patients with multiple cardiovascular and
noncardiovascular comorbidities, and diagnostic uncer-
tainty may sometimes delay the implementation of
appropriate treatment strategies. Treatment pathways may
vary depending on disease severity, the underlying cause,
and the classification (HFrEF, heart failure with midrange
ejection fraction, or heart failure with preserved ejection
fraction) of heart failure and may involve non-
pharmacological, pharmacological, and invasive (percuta-
neous or surgical) interventions [8]. In Disease Control
Priorities, Third edition, chapter 10, “Heart Failure,” offers a
summary report of heart failure interventions applicable
across geographic settings [77].
Medication may help to slow disease progression,
improve symptoms, and decrease hospital readmissions in
heart failure patients [76,78], yet adherence to medication
remains among the greatest perceived barriers to care
among health care professionals and researchers in car-
diovascular health [79e81]. This perception was reflected
in the WHF survey to Members with “adherence on
medication” reported as the greatest barrier (over 90%
agreement) to best-practice treatment. Additional barriers
include a low level of knowledge among patients about the
medication they are prescribed [82], and prescribed treat-
ment may not be in alignment with published guidelines
and evidence-based therapy [83].
An Integrated Approach to Address Roadblocks to
Treatment, Examples in Practice. There are a number
of trials and studies that support the positive effect of pa-
tient interventions pre-discharge and at 60 and 90 days
following hospital admission, particularly with regard to
medication adherence (IMPACT-HF [Initiation Manage-
ment Predischarge: Process for Assessment of Carvedilol
Therapy in Heart Failure] trial [84]; BRING-UP [Beta-
blockers in Patients With Congestive Heart Failure: Guided
Use in Clinical Practice] [85]; OPTIMIZE-HF [Organized
Program to Initiate Lifesaving Treatment in Hospitalized
Patients With Heart Failure] [86]). To design targeted in-
terventions, better understanding about the factors that
lead to poor adherence to medications from the patient and207
TABLE 3. An integrated approach to improving awareness of heart failure
Target Roadblock Possible Solutions
Patients, carers, families,
patient organizations,
and civil society
Lack of awareness and lack of
knowledge of heart failure
Support patient organizations to communicate with the general public, patients,
and caregivers by providing the information they need to empower patients to
make informed decisions on seeking treatment, identifying risks, and playing a
role in the management of their own health.
Patients, carers, families,
patient organizations,
and civil society
Harness advocacy as a powerful tool to bring together those with a common cause
to raise the profile of heart failure on national agendas, thereby raising
awareness of heart failure among patients, but also among decision and policy
makers.
Leaders in cardiovascular
health
Strengthen leadership among policy and decision makers, so they better recognize
and understand the challenges of heart failure care. Policy continues to fail in
making the essential link between scientific evidence to set policy decisions.
Leaders in cardiovascular
health
Drive action among leaders to reduce inequalities across geographic settings.
Strengthen communication across sectors to ensure alignment in strategies
from national to urban and rural settings with a view to putting heart failure
on national priority agendas.
Health care workers (primary
and secondary care setting)
Work collaboratively with patients to reduce their risk of developing heart failure
and help them to manage their health. Build evidence on the use of natriuretic
peptide-based screening and collaborative care.
Evidence in Practice
PAHO Rallies New Partners for Chronic Disease Prevention: the Pan American Health Organisation (PAHO) brought together health advocates across the
continent to become partners in a public-private effort to fight NCD focusing on key actions areas including changing policy, reducing risk factors, and
improving treatment.
“Policy makers’ perceptions of the high burden of heart disease in rural Australia” [57]: a paper highlighting inequality in resourcing, and political pressure
and education as key constraints to evidence-based policy in rural communities.
Pan African Ministries of health meeting on hypertension: an example of a regional meeting involving ministries of health, education, agriculture, transport
and finance, among other stakeholders, to support a move from science into policy and to leverage support for key recommendations in addressing
hypertension in Africa [58].
STOP-HF (Natriuretic peptide-based screening and collaborative care for heart failure) randomized study: the first reported example to show a reduction in
newly diagnosed heart failure, suggesting that a targeted strategy for the prevention of heart failure using natriuretic peptides and collaborative care in a
community population may be effective [54].
NCD, noncommunicable diseases.
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208community perspective is required. Studies for other
chronic conditions, such as the antiretroviral qualitative
study in human immunodeficiency virus (HIV) conducted
in South Africa [87], provide valuable insights into
population-specific challenges related to adherence.
The economic burden of heart failure, particularly the
cost related to hospitalizations, has generated research in-
terest into the various models of care that may improve
outcomes, particularly rehospitalization [88]. Several
studies have successfully shown the importance of
community-based programs in improving patient adher-
ence to medication [80,89] and reducing hospitalization
[90]. In an effort to improve medication adherence for
antiretroviral therapy in HIV, Antiretroviral Therapy
Clinics in South Africa have introduced a “dual solution
approach.” This approach focuses on pairing up “com-
munity-based patient follow-up programs and patient ed-
ucation” initiatives (discussed in more detail in the
Monitoring section) on key messages and specific infor-
mation considered essential for patients to manage their
disease.For other possible solution focused on treatment, see
Table 5 [89,91e94].Monitoring
Setting: Primary care, community care centers, home care
visits, specialist centers.
Heart failure monitoring refers to the follow-up of
patients to detect and treat the signs and symptoms of
heart failure to prevent disease progression. Recurrent
hospitalizations are common in heart failure [8,9] and
may be a consequence of disease progression, suboptimal
treatment, a lack of psychosocial support, poor diet and/
or impaired capacity for overall self-care [92,95]. A
collaborative multidisciplinary approach is often required
to reduce hospital readmissions and improve quality of
life [96,97]. A lack of knowledge of the purpose of
medications and how to self-manage symptoms of
deterioration [98,99] was the highest reported roadblock
to best patient care. Furthermore, a limited under-
standing of heart failure among patients and caregivers isGLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214
TABLE 4. An integrated approach to improve access to diagnostic tests
Targeted at Roadblocks Possible Solutions
Patients, carers, families,
patient organizations,
and civil society
Lack of access to primary care
clinics for diagnosis
Implement patient communication and education initiatives that are
essential to deliver best-practice care to heart failure patients. Early
detection and diagnosis are uniformly linked to awareness and
prevention. Recognizing the signs and symptoms of heart failure,
understanding specific risk factors, and communicating with health
care professionals is an essential step.
Leaders in cardiovascular
health
Lack of knowledge among the
general public to recognize
symptoms and seek medical
attention
Improve access for patients to overcome social inequalities and late
presentation due to poor education or rural isolation.
Invest in leadership and agency in health system planning to set up
decentralized heart failure clinics linked to centralized advanced
treatment centers.
Health care workers (primary
and secondary care setting)
Support patients with low health literacy using e-health in a
collaborative approach to care.
Appoint experts to lead heart failure care and advocacy across settings
and disciplines. This is an evidence-based consensus policy
recommendation that focuses on an integrated approach to care to
develop protocols, training and local auditing [74].
Evidence in Practice
Decentralized heart failure centers established linked to a centralized care unit across South India to improve access for patients: this intervention has yet to
be published but was shared with WHF during the survey process.
HeLP-GP (Health eLiteracy for prevention in General Practice) intervention from Australia [75]: this study investigates the impact and outputs of a mobile
health application for adults with lower levels of health literacy in the primary care setting.
WHF, World Heart Federation.
gRECSjreflected by reports of poor correlation between symp-
toms, such as breathlessness, and the disease itself
[44,45,98].
An Integrated Approach to Address Roadblocks to
Monitoring, Examples in Practice. Patient education:
Educating patients is central to patient care and has been
shown to improve patient outcomes and quality of lifeTABLE 5. Other possible solutions focused on treatment
Targeted at Roadblock
Patients, carers, and health care
professionals
Lack of
medication
adherence
Encoura
Equip pa
Impleme
Leaders in cardiovascular health The trea
adhe
Policy in
med
impr
Health care workers (primary and
secondary care setting)
Take a c
to m
Evidence in Practice
World Health Organization and Sri Lanka study: underlines effe
Copayment reductions: generate greater medication adherence
Pharmacist intervention to improve medication adherence in h
GLOBAL HEART, VOL. 14, NO. 3, 2019
September 2019: 197-214[99,100]. There are numerous approaches to patient
education, and consideration of different learning styles
in the dissemination of key messages is essential when
choosing an approach. The use of blended learning and
a multimethod approach tailored to patient needs may
be required [101,102]. In addition, follow-up programs
must consider the most appropriate intervention for each
patient according to their specific needs [103]. ThePossible Solutions
ge informed decision making with patients and carers.
tient education initiatives with behavioral supports to improve medication adherence.
nt patient education programs and interventions to support treatment adherence.
tment of patients with a polypill that is affordable [91] is well reported to improve
rence. This solution could well be adapted for heart failure [92].
terventions that reduce direct costs to patients for prescriptions through reduced
ication copayments or improved prescription drug coverage have been shown to
ove adherence to medication.
ollaborative approach to care that has been shown to systematically improve adherence
edications.
ctiveness and safety of treating patients with a polypill [93].
in targeted patients 2010 [94].
eart failure: a randomized trial 2007 [89].
209
TABLE 6. An integrated approach to improving patient monitoring and follow-up
Targeted at Roadblock Possible Solution
Patients, carers, families,
patient organizations, and
civil society
Lack of follow-up programs
for patients
Improve health literacy among patients through targeted programs.
Education for self-care through follow-up programs has been shown
to have a positive impact on reduced mortality and reduced
hospitalization.
Leaders in cardiovascular
health
Lack of collaboration across care
settings
Implement education and capacity-building programs for health care
professionals at primary and community care level as a first-line
approach to improving monitoring and follow-up of patients.
Health care workers (primary
and secondary care setting)
Implement interventions and follow-up treatment programs, including
mHealth and e-health interventions. Where this may be difficult to
achieve telephone support services have also shown better self-care
behavior.
Evidence in Practice
CardioMEMS heart failure system (Abbott, Abbott Park, Illinois), which measures the pulmonary artery pressure and heart rate through an implanted
sensor: daily blood pressure readings transmit data to either a primary care or specialist doctor supporting continuous monitoring [107].
“Effect of a medication-taking behavior feedback, theory-based intervention on outcomes in patients with heart failure” 2011 [108].
DIAL (Randomised trial of telephone intervention in chronic heart failure) trial, which tested the effectiveness of a telephone-based intervention coveringmore
than 50 centers and 1,500 patients: highlighted the positive impact of this follow-up program to reduce heart failure hospital admissions by 30% [106].
j gRECS
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the setting, the health care team, and how civil society
organizations deliver key disease messages. Educational
frameworks and design methodology are essential
considerations in implementing effective education pro-
grams [104].
Disease management: A recent Cochrane review evalu-
ated the role of disease management for patients with heart
failure. Disease management refers to a model of care that
emphasizes proactive and preventive care in hospitals,
clinics, or homes, rather than crisis intervention as per the
traditional model. These models are typically run by nurses
and/or multidisciplinary teams. Data from 47 randomized
clinical studies (10,869 participants) suggested that case
management and multidisciplinary interventions may
reduce all-cause mortality; however, there is limited evi-
dence that disease management decreases hospital read-
missions or heart failureerelated deaths. Although
promising, the overall quality of evidence is low and most
of the studies related to disease management have been
conducted in high-income countries [105].
Telemonitoring: Another recent Cochrane review eval-
uated the role of noninvasive home telemonitoring and
telephonic support for people with heart failure [106]. The
review identified 41 randomized controlled trials: 25
studies (9,332 participants) evaluating telephonic support,
and 18 evaluating telemonitoring (3,860 participants).
Only 2 studies evaluated both interventions and most of
the studies were conducted in high-income countries.
There was moderate evidence that home telemonitoring or
telephonic support reduces all-cause mortality and hospi-
talization due to heart failure.
Whereas interventions such as education, multidisci-
plinary teams, disease management, and technology forGLOBAL HEART, VOL. 14, NO. 3, 201
September 2019: 197-21monitoring are promising, their implementation and sus-
tainability in real-world settings remain a challenge. Further
implementation research is needed to fully understand how
these complex interventions affect patient care and out-
comes, particularly in LMIC where there is a paucity of data.
For an integrated approach to improving patient
monitoring and follow-up, see Table 6 [106e108].ADAPTING TO NATIONAL ROADMAPS—FROM
PRESCRIBED RECOMMENDATIONS TO PRACTICE
IMPLEMENTATION
This Roadmap describes an ideal continuum of care
pathway for heart failure, explores the roadblocks along
this pathway, and considers potential solutions based on
available research and examples in practice. To move from
prescribed global recommendations to local and national
implementation, a number of specific actions are required
to plan, design, and implement change. Previous Road-
maps have outlined steps for adapting suggested frame-
works at the national level: multisectorial coalition;
situational analyses to consider the national needs, the
health care system, and policy environment; policy di-
alogues to identify and discuss specific barriers and po-
tential strategies; and plan of action to design and
implement specific interventions [4]. These steps provide
guidance in the development of a call for action for
improving heart failure care and reducing the burden of
this rising epidemic. This process is well described in
previous Roadmap recommendations [1e6].
The WHF implementation toolkit (Figure 6) offers a
step-by-step approach to specific action areas and highlights
the importance of an integration across multiple care set-
tings. Tomove from a global Roadmap initiative to a national9
4
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call for action to service implementation, strong leadership
and integration between sectors is required, including na-
tional ministries of health, education, labor, finance, and
transport; health care system decision makers; health care
professionals; and representatives from industry, patients,
carers, and civil society. Bringing key leaders and stake-
holders together for national Roundtable discussions to
consider a unified heart failure agenda based on national and
local needs is considered a necessary first step.
WHF continues to support national and regional so-
cieties and Members to raise the profile of heart failure as a
priority area, by facilitating national Roundtable stake-
holder discussions, national scorecards, and by creating a
global network of research, through initiatives such as the
WHF Emerging Leaders program, in addition to providing
supporting toolkits for implementation and guidance in
key actions areas such as advocacy. All WHF initiatives are
aimed at supporting national efforts to reduce the growing
burden of heart failure.disseminaƟon
and implementaƟon
Define scale-up
plan
Define project as
a long term iniƟaƟve
Monitoring and
evaluaƟon tools
6
7
FIGURE 6. Implementation toolkit.FINAL CONSIDERATIONS FOR THE FUTURE OF
HEART FAILURE PATIENTS
With an estimated 26 million individuals living with heart
failure globally [16], the burden of heart failure is felt at
every level of health care: for systems and health care
workers confronted by greater numbers of ill patients; and
for health economies faced with increasing costs associated
with heart failure. Social and geographic inequalities add to
this burden for those most vulnerable. Despite challenges
in the delivery of high-quality care to heart failure patients,
there are many examples of successful interventions that
have been implemented in various socioeconomic settings
that may pave the way for a brighter future for heart failure
patients.
This WHF Heart Failure Roadmap offers an outline of
an ideal continuum of care pathway for heart failure that is
relevant across all countries and regions. Specific road-
blocks may differ depending on local context. By raising
awareness of heart failure among health care professionals
and key stakeholders, addressing the inequities of care to
patients with heart failure, highlighting common chal-
lenges in the delivery of care globally, and bridging the care
gap between knowledge and implementation, this Heart
Failure Roadmap provides a platform on which to build
services that prioritize patients and improve outcomes for
heart failure patients.ACKNOWLEDGMENTS
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